Search clinical trials for: tapentadol (CG5503) Extended Release (ER)

Total 784 results

Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain

Low Back Pain
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers

Healthy Volunteer
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet

Healthy Volunteer
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

Pain | Osteoarthritis | Low Back Pain

United States, Australia, Canada, New Zealand
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet

Healthy Volunteer
Ultragenyx Pharmaceutical Inc

Completed

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (GNE Myopathy)

Hereditary Inclusion Body Myopathy | GNE Myopathy

United States, Israel
Ultragenyx Pharmaceutical Inc

Completed

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (GNEM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Ultragenyx Pharmaceutical Inc

Terminated

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Hereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

Canada, United States, Bulgaria
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Arthritis | Joint Diseases | Osteoarthritis
Ultragenyx Pharmaceutical Inc

Terminated

Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
Zogenix, Inc.

Completed

A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery

Postoperative Pain
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Pain | Lower Back Pain | Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Canada
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study to Evaluate the Dose-Proportionality of Tramadol (ULTRAM) Extended-Release (ER) in Healthy Participants

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Terminated

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Diabetic Neuropathy, Painful | Diabetic Polyneuropathy

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathy

United States, Canada, Puerto Rico
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Low Back Pain
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet

Healthy

United States
University of Arizona
National Cancer Institute (NCI)

Recruiting

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

Oral Leukoplakia | Erythroplakia

United States, Canada
National Cancer Institute (NCI)

Recruiting

Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

Lung Carcinoma

United States, Canada
Matthew Neal MD
Berry Consultants; University of Pittsburgh Medical Center

Completed

REMAP Trial for Optimizing Surgical Outcomes at UPMC (UPMCREMAP)

Aging

United States
UConn Health

Completed

Vaccination Efficacy With Metformin in Older Adults (VEME)

Aging | Vaccine Response Impaired | Age-Related Immunodeficiency

United States
Zogenix, Inc.

Completed

A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain

Osteoarthrosis
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers

Healthy
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Gwendolyn Sowa

Completed

Effects of Metformin on Low Back Pain

Low Back Pain

United States
James Wang
United States Department of Defense

Recruiting

Managing Chronic Tendon Pain by Metformin

Chronic Pain | Tendinopathy | Achilles Tendinopathy

United States
Laboratorios Silanes S.A. de C.V.

Completed

Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)

Healthy

Mexico
Woman's
Pfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...

Withdrawn

Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer (METBC)

Insulin Resistance | Breast Cancer Stage | Racial Bias

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effects of Niacin Therapy on Lipoprotein Composition and Function

Cardiovascular Disease

United States
Janssen Scientific Affairs, LLC

Withdrawn

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

Pain | Chronic Low Back Pain | Chronic Back Pain | Osteoarthritis Pain In The Hip or Knee

United States
Grünenthal GmbH
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Pain | Tumor

Austria, Bulgaria, Croatia, Czechia, France, Germany, Hungary, Italy, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, Slovakia, Spain, Sweden
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Metformin and Nightly Fasting in Women With Early Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma

United States, Italy
Murdoch Childrens Research Institute

Recruiting

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC) (MARVEL-PIC)

Neoplasms | Bone Marrow Transplantation

Australia
Samsung Medical Center
Pfizer

Completed

Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder

Overactive Bladder

Korea, Republic of
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants

Healthy

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence (TACT2)

Cocaine Dependence

United States
OPKO Health, Inc.

Completed

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

Covid19 | Coronavirus | SARS-CoV-2 Infection

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery

Osteoarthritis | Arthralgia | Pain Assessment
Depomed

Completed

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

Hot Flashes

United States
Hadassah Medical Organization

Completed

Efficacy of Sialic Acid GNE Related Thrombocytopenia (SA-thrombo)

Thrombocytopenia
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)

Alzheimer's Disease

United States, Australia, Spain, Bulgaria, Poland, Germany, Philippines, Singapore, Belgium, Canada, Hong Kong, Korea, Republic of, Finland, Slovenia, Czechia, France, South Africa, Sweden, Netherlands, Malaysia, United Kingdom, S...

3

Subscribe